The race to build the best artificial intelligence model for medicine is over; the real competition now is about who controls the data. As large language models (LLMs) and other AI systems become increasingly accessible, the scarce resource is no longer raw computing power or algorithmic innovation, but rather the proprietary datasets locked inside research institutions and health systems that can train and validate AI tools in real-world clinical settings.

What Changed in the AI-Medicine Landscape?

For years, the headline-grabbing breakthroughs in AI and healthcare centered on model architecture and scale. AlphaFold, DeepMind's protein-folding system, captured global attention by solving a 50-year-old problem in structural biology. But as foundation models have proliferated and become more commoditized, the competitive advantage has shifted dramatically. The labs that will shape medicine over the next decade are not necessarily those with the biggest models, but those with the most valuable clinical data and the relationships to validate what their AI systems actually do in practice.

This shift reflects a fundamental truth: intelligence itself is becoming rentable by the token, meaning companies and researchers can access powerful AI capabilities on demand. What they cannot easily replicate is decades of outcomes data, patient records, and clinical validation that only established health systems and research institutions possess.

Which Labs Are Positioned to Lead?

Several organizations stand out as the ones to watch, not because they have the most advanced models, but because of the datasets and clinical relationships they control:

• DeepMind: The parent organization behind AlphaFold, which continues to push the frontier of biology and medicine by solving problems the field considered permanently stuck.
• Anthropic: Its Claude models now power enterprise healthcare deployments, including Banner Health's rollout to more than 55,000 employees, with a stated focus on safety in high-stakes medical settings.
• Microsoft and Abridge: The combination behind Dragon Copilot, an ambient documentation tool deployed across hundreds of health systems and deeply integrated into Epic, the most widely used electronic health record system.
• Mayo Clinic: A health system running as a research lab, co-developing AI on one of the richest de-identified clinical datasets available, including work on palliative care identification and nurse-focused documentation.
• Mount Sinai: Built a model that recommends against blood thinners in up to half of certain atrial fibrillation patients, and signed the first enterprise OpenEvidence deal, demonstrating how academic centers are quietly producing clinical AI that changes real medical decisions.

The common thread across all these organizations is not model size or computational resources. Instead, it is proprietary data combined with clinical validation. These labs own datasets and clinical relationships that no amount of compute can conjure from scratch.

How Anthropic Is Betting on Data-Driven Science

Anthropic's recent launch of Claude Science, a specialized workbench designed for scientific research, illustrates how AI companies are now building tools around data workflows rather than just releasing more powerful models. The platform, which Anthropic has been developing since October 2025, combines coding tools, processing power, and scientific databases into a single interface tailored for academic and medical research.

Claude Science comes pre-configured with more than 60 massive scientific databases and can natively render complex technical visualizations, including 3D protein structures, chemistry molecular models, and genome browser tracks. The system allows researchers to instantly review and cross-reference thousands of pages of existing medical literature, process raw data, and generate publication-ready charts and manuscript drafts.

"Claude Science runs on our existing family of advanced models and has successfully cleared our responsible scaling policies and specialized biosecurity evaluations to ensure the powerful technology cannot be misused," explained Eric Kauderer-Abrams, Anthropic's Head of Life Sciences.

Eric Kauderer-Abrams, Head of Life Sciences at Anthropic

More significantly, Anthropic announced it is launching its own internal, pre-clinical drug discovery programs and plans to use Claude Science to hunt for treatments for neglected diseases. This move signals that even AI companies are recognizing that building proprietary datasets and clinical validation pipelines is essential to competing in healthcare.

Steps to Understanding the New Data Moat in AI Medicine

• Recognize the Shift: Intelligence is becoming a commodity available through APIs and cloud services, so the competitive advantage moves from model architecture to proprietary datasets and clinical validation.
• Identify Data Holders: Health systems, academic medical centers, and research institutions with decades of de-identified patient outcomes data are now the most valuable players in AI-driven drug discovery and clinical care.
• Evaluate Clinical Validation: The labs that matter most are those that can not only build AI tools but also validate them in real clinical settings with actual patient outcomes, not just benchmark scores.

The implications are profound. A model you can rent from a cloud provider is interchangeable with dozens of others. But a dataset of 20 years of cardiac outcomes from Mayo Clinic, or a validated clinical workflow embedded in Epic across hundreds of hospitals, is irreplaceable. As foundation models turn intelligence into a commodity, the scarce thing becomes proprietary data and the labs that generate it.

For researchers, clinicians, and investors watching the AI-medicine space, the lesson is clear: pay less attention to which company releases the next breakthrough model, and more attention to which organizations are quietly building the datasets and clinical partnerships that will define medicine in the next decade.